The new American Society of Clinical Endocrinology Guidelines for Clinical Practice recommends the Echosens VCTE FibroScan Technology page 1

echoThe high-tech company and FibroScan solution group provider is pleased to announce this in Guidelines American Association of Clinical Endocrinologists for Clinical Practice of Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Clinical Endocrinology This means that quantitative transient elastic (TE) quantification of hepatic lipids (CAP) and fibrosis and vibrating-controlled elastic transient elasticities (VCTE) is best for risk classification. It is very clear from these guidelines that clinicians should use a VCTE–such as a FibroScan–to estimate the risk of fibrosis in people with NAFL because it is the best way to identify advanced disease and the most predictive of liver disease outcomes that can become.

For more information, please refer to the information sheet:
United States of America: https://www.ehosens.com/en-us/aace-clinical-practice-guidelines-2022/
worldwide: https://www.ehosens.com/aace-clinical-practice-guidelines-2022/

“This technology provides an ideal avenue for early identification of high-risk patients to prevent the development of cirrhosis and comorbidities based on screening procedures for patients at risk of developing cirrhosis (FIB-4),” said Dominique Legros, CEO of the Echosens Group. “Thereafter, further plasma biomarkers and/or liver imaging should be determined based on fibrosis risk stratification into low, nonspecific, or high risk of developing cirrhosis in the future, with referral to a hepatologist for patients in high-risk groups.”

As a leader in flexible imaging of the liver, FibroScan is recognized worldwide as the non-invasive gold standard for the assessment of cirrhosis and steatosis. There are more than 3,500 specialized publications on this topic. The non-invasive technique provides a rapid quantitative assessment of liver stiffness and controlled attenuation (CAP) criteria at point of care, associated with cirrhosis and hepatic steatosis, respectively.

The AACE guidelines also recommend repeating the test every two years in low-risk patients because one study showed that only a minority would develop a higher stage of fibrosis within this time frame.